Prestige Consumer Healthcare (PBH) Cash from Investing Activities Growth (1y) (2011 - 2025)
Prestige Consumer Healthcare (PBH) Cash from Investing Activities Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.43 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,209.70% |
| Sep 30, 2025 | -44.50% |
| Jun 30, 2025 | 9.01% |
| Mar 31, 2025 | 76.81% |
| Dec 31, 2024 | -118.33% |
| Sep 30, 2024 | 30.91% |
| Jun 30, 2024 | -191.69% |
| Mar 31, 2024 | -135.99% |
| Dec 31, 2023 | -149.36% |
| Sep 30, 2023 | -23.48% |
| Jun 30, 2023 | 321.87% |
| Mar 31, 2023 | -93.08% |
| Dec 31, 2022 | 91.09% |
| Sep 30, 2022 | 98.97% |
| Jun 30, 2022 | 20.86% |
| Mar 31, 2022 | 32.74% |
| Dec 31, 2021 | -253.16% |
| Sep 30, 2021 | -2,455.33% |
| Jun 30, 2021 | 48.18% |
| Mar 31, 2021 | 40.76% |